Sunesis Pharmaceuticals Announces Global Licenses for Two Kinase Inhibitor Programs

Sunesis Pharmaceuticals

today announced that it has expanded its hematology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec

, is for global commercial rights to SNS-062, a potent and selective non-covalently binding oral inhibitor of BTK (Bruton's tyrosine kinase).